Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis

• US 20080095761A1
• Filed: 10/01/2004
• Published: 04/24/2008
• Est. Priority Date: 10/01/2003
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Karhadkar, Sunil S., Berman, David M., Beachy, Philip A.
• Application Number:
  US10/572,430
• Publication Number:
  US 20080095761A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/46 from vertebrates
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: G01N 2333/46 from vertebrates
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a prostate tumor to treatment with an Hh pathway antagonist.

Claims

1. A method of reducing or inhibiting proliferation or metastasis of cells of a prostate tumor characterized by elevated Hedgehog (Hh) pathway activity as compared with a normal cell, comprising contacting the cells with at least one Hh pathway antagonist, thereby reducing or inhibiting proliferation of the cells of the prostate tumor.

2. The method of claim 1, wherein the prostate tumor is a malignant tumor.

3. The method of claim 1, wherein the elevated Hh pathway activity comprises elevated ligand stimulated Hh pathway activity.

4. The method of claim 3, wherein the ligand comprises Sonic hedgehog (SHH) or Indian hedgehog (IHH) or a combination thereof.

5. The method of claim 1, wherein the Hh pathway antagonist comprises a steroidal alkaloid or derivative thereof.

6. The method of claim 5, wherein the steroidal alkaloid is cyclopamine.

7. The method of claim 1, wherein the Hh pathway antagonist is a nucleic acid or a protein molecule.

8. The method of claim 7, wherein the protein molecule is an antibody.

9. The method of claim 1, further comprising contacting the cells with a chemotherapeutic agent.

10. The method of claim 6, further comprising contacting the cells with an antibody.

11. The method fo claim 10, wherein the antibody is anti-Hh antibody.

12. A method of ameliorating a prostate tumor in a subject, comprising administering to the subject an Hh pathway antagonist, whereby the Hh pathway antagonist contacts cells of the tumor in the subject, thereby ameliorating the prostate tumor in the subject.

13. The method of claim 12, wherein the prostate tumor is a malignant tumor.

14. The method of claim 12, wherein the elevated Hh pathway activity comprises elevated ligand stimulated Hh pathway activity.

15. The method of claim 14, wherein the ligand comprises Sonic hedgehog (SHH) or Indian hedgehog (IHH).

16. The method of claim 12, wherein the Hh pathway antagonist comprises a steroidal alkaloid or derivative thereof.

17. The method of claim 16, wherein the steroidal alkaloid is cyclopamine.

18. The method of claim 12, further comprising administering to the subject a chemotherapeutic agent.

19. The method of claim 17, further comprising contacting the cells with an antibody.

20. The method fo claim 19, wherein the antibody is anti-Hh antibody.

21. The method of claim 12, wherein the Hh pathway antagonist is administered orally.

22. A method of identifying a prostate tumor of a subject amenable to treatment with a Hedgehog (Hh) pathway antagonist, comprising detecting elevated Hh pathway activity in a sample of cells from the subject as compared to Hh pathway activity in corresponding normal cells, thereby identifying a prostate tumor of a subject amenable to treatment with an Hh pathway antagonist.

23. The method of claim 22, wherein the cells are from a biopsy sample obtained from the subject.

24. The method of claim 22, wherein the cells are from a bodily fluid obtained from the subject.

25. The method of claim 22, wherein the elevated -Hh pathway activity comprises ligand stimulated Hh pathway activity.

26. The method of claim 22, comprising detecting elevated expression of at least one Hh pathway polypeptide.

27. The method of claim 26, wherein the Hh pathway polypeptide comprises an Bh ligand, an Hh ligand receptor, or a transcription factor.

28. The method of claim 27, wherein the Hh ligand comprises Sonic hedgehog (SHH), Indian hedgehog (IHH), or a combination thereof.

29. The method of claim 27, wherein the Hh ligand receptor comprises Patched.

30. The method of claim 27, wherein the transcription factor comprises a GLI-1 transcription factor.

31. The method of claim 26, which comprises detecting elevated levels of a polynucleotide encoding the Hh pathway polypeptide.

32. The method of claim 31, wherein the polynucleotide comprises RNA.

33. The method of claim 26, which comprises performing a reverse transcription-polymerase chain reaction.

34. The method of claim 26, which comprises detecting elevated levels of the Hh pathway polypeptide.

35. The method of claim 34, which comprises performing an immunoassay.

36. The method of claim 34, wherein the Hh pathway polypeptide comprises a transcription factor.

37. The method of claim 36, which comprises detecting increased binding activity of the transcription factor to a cognate transcription factor regulatory element.

38. The method of claim 36, which comprises detecting increased expression of a reporter gene comprising a cognate transcription factor regulatory element.

39. The method of claim 22, which comprises detecting altered expression of a transcriptional target of the Hh pathway.

40. The method of claim 39, which comprises detecting increased expression of a gene that is positively regulated by GLI-1 or GLI-2.

41. The method of claim 39, which comprises detecting decreased expression of gene that is negatively regulated by GLI-3.

42. The method of claim 22, comprising detecting decreased expression of at least one Hh pathway polypeptide.

43. The method of claim 42, wherein the Hh pathway polypeptide comprises a GLI-3 transcription factor.

44. The method of claim, 22, further comprising contacting cells of the sample with at least one Hh pathway antagonist, and detecting a decrease in Hh pathway activity in the cells following said contact, thereby confirming that the prostate tumor is amenable to treatment with an Hh pathway antagonist.

45. The method of claim 44, wherein the antagonist is cyclopamine.

46. The method of claim 45, further comprising contacting the cells with a chemotherapeutic agent.

47. The method of claim 45, further comprising contacting the cells with an anti-Hh antibody.

50. The method of claim 39, wherein the agent comprises an Hh pathway antagonist.

51. The method of claim 50, wherein the antagonist comprises steroidal alkaloid or a derivative thereof.

52. The method of claim 51, wherein the steroidal alkaloid is cyclopamine.

48. A method of identifying an agent useful for treating a prostate tumor or metastatsis wherein the tumor cells have elevated Hedgehog (Hh) pathway activity, comprising contacting a sample of cells of a prostate tumor with at least one test agent, wherein a decrease in Hh pathway activity in the presence of the test agent as compared to Hh pathway activity in the absence of the test agent identifies the agent as useful for treating the prostate tumor.

49. The method of claim 48, wherein the elevated Hh pathway activity comprises elevated ligand stimulated Hh pathway activity.

53. The method of claim 48, which is performed in a high throughput format.

54. The method of claim 53, comprising contacting samples of cells of a plurality of samples with at least one test agent.

55. The method of claim 54, wherein plurality of samples are obtained from a sinlgle-suect.

56. The method of claim 54, wherein the plurality of samples are obtained from different subjects.